Shimomura and colleagues recently investigated molecular targets for K-RAS-activated lung cancer in K-RAS-mutant and wild-type lung cancer cell lines using a drug library of 1271 small molecules, and identified the cytotoxic effects of benzimidazole derivatives on K-RAS-mutant lung cancer cells [19]. This evidence concerns the gene KRAS and lung cancer.